A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
Status:
Completed
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The main aim of this study is to find out how the body of a healthy adult processes TAK-279
(pharmacokinetics) when substances that either hinder or help the human metabolism such as
erythromycin, phenytoin and efavirenz are given along with TAK-279. Other aim is to learn
about side effects and how well it is tolerated when TAK-279 is given alone and together with
substances that impact human metabolism.
The participants will need to stay at the clinic for up to 26 days.